A prospective randomized, multicenter trial evaluating the efficacy and safety of combined therapy with pirfenidone and inhaled N-acetylcysteine for idiopathic pulmonary fibrosis. - Combined therapy with pirfenidone and inhaled N-acetylcysteine for idiopathic pulmonary fibrosis.

Grant for Research on Diffuse Lung Disease from the Ministry of Health, Labour and Welfare of Japan.0 个研究点目标入组 81 人开始时间: 2014年10月24日最近更新: 2023年10月17日

适应症

试验速览

There was no difference between the two groups in the of change in FVC.

•1.coexisting severe cardiovascular disease 2.coexisting severe liver disfunction 3.coexisting chronic kidney disease 4.patients who had a history of receiving chemotherapy or thoracic radiotherapy 5.patients who are pregnant or possibly pregnant, or nursing 6.patients who were unable to undergo physiologic tests 7.candidates for lung transplantation 8.improving physiologic tests or HRCT findings compared with previous 6 months. 9.patient who were administered with 20 mg/day or more of predonisolone during the preceding 3 months. Treated with NAC or nintedanib during the preceding 3 months. 10.treated with immunosuppressive agents. 11.coexisting pulmonary arterial hypertension, bronchial asthma,sarcoidosis,bronchiectasis, neoplasm,infectious disease. 12.patients who participated in another clinical study within 3 months prior to the administration period of the study drug. 13.considered ineligible for the study by the investigator.

发起方

Grant for Research on Diffuse Lung Disease from the Ministry of Health, Labour and Welfare of Japan.